The global gaucher disease (GD) drugs market size is expected to reach USD 1.71 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 1.1% during the forecast period. The growing prevalence of the disease and increasing research and development activities in the field are likely to help the market in gaining momentum over the coming years. With high unmet needs, there is a strong need for the development of novel treatments with improved efficacy in neuronopathic complications, convenient dosage, and reduced cost.
Gaucher
disease is a genetic metabolic disorder, caused by mutations in GBA gene.
People with Gaucher disease produce low glucocerebrosidase (GCase), an enzyme
required to degrade glucocerebroside. Excess accumulation of lipids in spleen,
liver, kidney, brain, lungs, and bone marrow impedes the normal functioning of
the organs.
In
spite of being the most prevalent lysosomal storage disorder, Gaucher disease
is a rare condition with an average prevalence of 1 in 100,000 individuals.
However, certain ethnic races such as Ashkenazi Jews are more susceptible to
this disorder. Ashkenazi Jews have an average disease prevalence of 1 in 500
individuals.
Currently,
type 1 is the most common form of Gaucher disease. This condition is
nonneuronopathic in nature, as it does not affect the central nervous system
(CNS). Type 1 GD commanded more than 75.0% of the market in 2017. It is
estimated to retain its position through 2025. Type 2 and type 3 are not as
common as type 1.
On
the basis of treatment, enzyme replacement therapy (ERT) was the leading
revenue contributor in the market in 2017. The growth of the segment can be
attributed to the strong sales of Cerezyme and Vpriv. However, there has been
an increase in inclination towards substrate replacement therapy (SRT),
spearheaded by Cerdelga and Zavesca. ERT is mostly indicated for type 1 and
type 3 (to address issues unrelated to the CNS), as replacement enzymes cannot
penetrate blood brain barrier. Additionally, there is no effective treatment
for type 2.
Full Research Report On Gaucher Disease Drugs Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/gaucher-disease-drugs-market
Gaucher Disease
Drugs Market Report Highlights
- Type 2 is the
rarest of the three forms of GD, with an average mortality rate of less
than two years
- Enzyme
replacement therapy dominated the treatment landscape, headed by Sanofi
Genzyme’s Cerezyme. However, GD treatment is witnessing a shift towards
substrate replacement therapy, which is anticipated to register a CAGR of
over 7.5% during the forecast period
- The U.S.
spearheaded the major markets, in terms of sales as well as disease
burden. The country will continue to dominate the market through 2025, on
account of widening the patient base and easy accessibility to treatments
- Some of the
prominent companies operating in the market are Sanofi Genzyme, Shire,
Pfizer, and Johnson & Johnson
- Sanofi
Genzyme led the competitive space and is projected to continue holding a
prominent position in the market over the coming years, due to significant
commercial performances of Cerezyme and Cerdelga
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/gaucher-disease-drugs-market/request/rs1
Gaucher Disease
Drugs Market Segmentation
Grand View Research has
segmented the global Gaucher disease drugs market based on type, therapy, and
country:
Gaucher Disease
Drugs Type Outlook (Revenue, USD Million, 2017 - 2025)
- Type 1
- Type 2
- Type 3
Gaucher Disease
Drugs Therapy Outlook (Revenue, USD Million, 2017 - 2025)
- Enzyme Replacement Therapy
- Substrate Replacement Therapy
Gaucher Disease
Drugs Country Outlook (Revenue, USD Million, 2017 - 2025)
- The U.S.
- The U.K.
- Germany
- Spain
- France
- Italy
- Japan
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment